Skip to content
lifestyle.thriveinsider.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Sobi, Inc.
Sobi Receives US FDA Fast Track Designation for pacritinib in VEXAS Syndrome
September 10, 2026
Canada’s Drug Agency Issues Positive Reimbursement Recommendation for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
July 9, 2026